Aduro plans to use the new capital to advance its lead program in metastatic pancreatic cancer through its ongoing Phase 2b ECLIPSE clinical trial, to continue clinical development in mesothelioma and high-grade glioma, to expand into additional indications and to advance its small molecule program targeting the immunomodulatory STING receptor.
